Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
LNTH 
Lantheus Holdings Inc (LNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: LNTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $82.79
1 Year Target Price $82.79
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.55% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.61B USD | Price to earnings Ratio 28.15 | 1Y Target Price 82.79 |
Price to earnings Ratio 28.15 | 1Y Target Price 82.79 | ||
Volume (30-day avg) 13 | Beta -0.11 | 52 Weeks Range 47.25 - 111.29 | Updated Date 01/9/2026 |
52 Weeks Range 47.25 - 111.29 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.99% | Operating Margin (TTM) 11.36% |
Management Effectiveness
Return on Assets (TTM) 9.93% | Return on Equity (TTM) 14.59% |
Valuation
Trailing PE 28.15 | Forward PE 11.88 | Enterprise Value 4736685205 | Price to Sales(TTM) 3.02 |
Enterprise Value 4736685205 | Price to Sales(TTM) 3.02 | ||
Enterprise Value to Revenue 3.1 | Enterprise Value to EBITDA 14.49 | Shares Outstanding 66311779 | Shares Floating 61476987 |
Shares Outstanding 66311779 | Shares Floating 61476987 | ||
Percent Insiders 2.32 | Percent Institutions 110.67 |
Upturn AI SWOT
Lantheus Holdings Inc
Company Overview
History and Background
Lantheus Holdings Inc. was founded in 1946 and has evolved into a leading medical imaging and radiopharmaceutical company. Significant milestones include its separation from Bristol-Myers Squibb in 2001 and its subsequent acquisition by Avista Capital Partners in 2014, followed by its IPO in 2015. The company focuses on developing and commercializing innovative diagnostic and therapeutic products.
Core Business Areas
- Diagnostic Imaging: This segment focuses on providing radiopharmaceuticals and contrast agents used in various medical imaging procedures such as PET (Positron Emission Tomography) and SPECT (Single-Photon Emission Computed Tomography) scans. These products aid in the detection, diagnosis, and monitoring of diseases.
- Therapeutic Radiopharmaceuticals: This emerging segment is dedicated to developing and commercializing radiopharmaceuticals for the treatment of various cancers. These therapies deliver targeted radiation directly to cancer cells.
Leadership and Structure
Lantheus Holdings Inc. is led by a seasoned management team with expertise in the pharmaceutical and medical device industries. The organizational structure is designed to support its R&D, manufacturing, sales, and marketing operations, with a focus on its core business segments.
Top Products and Market Share
Key Offerings
- Product Name 1: DEFINITYu00ae (Perflutren Lipid Microsphere / Octafluoropropane) Injectable Suspension. DEFINITY is a contrast agent used to improve the visualization of cardiac structures during ultrasound imaging. It is a leading product in its category. Competitors include GE Healthcare, Philips, and Siemens Healthineers in the broader medical imaging contrast agent market.
- Product Name 2: PYLARIFYu00ae (Taurine 18F) Injection. PYLARIFY is a PSMA-targeted PET imaging agent used for the detection and staging of prostate cancer. It represents a significant advancement in prostate cancer diagnostics. Competitors in the PSMA PET imaging space include others developing similar targeted radiopharmaceuticals.
- Product Name 3: Xenon Xe 133. This is a radioactive gas used for lung ventilation imaging, often in conjunction with perfusion imaging. Competitors include other providers of diagnostic radiopharmaceuticals for pulmonary imaging.
Market Dynamics
Industry Overview
The medical imaging and radiopharmaceutical industry is characterized by continuous innovation, driven by the demand for earlier and more accurate disease detection and personalized treatment. Key trends include the growth of molecular imaging, the development of targeted therapies, and an aging global population contributing to increased healthcare needs. Regulatory landscapes and reimbursement policies significantly influence market access and adoption.
Positioning
Lantheus Holdings Inc. is positioned as a leader in diagnostic imaging agents and is rapidly growing its presence in therapeutic radiopharmaceuticals. Its competitive advantages lie in its established product portfolio, strong R&D pipeline, strategic partnerships, and growing commercialization capabilities, particularly in oncology.
Total Addressable Market (TAM)
The Total Addressable Market for medical imaging agents and radiotherapeutics is substantial and growing, driven by increased diagnostic procedures and the expanding oncology market. Lantheus Holdings Inc. is well-positioned to capture a significant portion of this market, particularly in its areas of specialization, with PYLARIFY targeting the large and growing prostate cancer market.
Upturn SWOT Analysis
Strengths
- Established presence in diagnostic imaging with well-recognized products.
- Strong R&D pipeline, particularly in therapeutic radiopharmaceuticals.
- Strategic focus on high-growth areas like oncology.
- Experienced management team with industry expertise.
- Growing commercialization capabilities.
Weaknesses
- Reliance on a few key products for a significant portion of revenue.
- Competition from larger, more diversified healthcare companies.
- The radiopharmaceutical market is complex and requires specialized infrastructure and expertise.
- Potential for pricing pressures and reimbursement challenges.
Opportunities
- Expansion of its therapeutic radiopharmaceutical portfolio.
- Geographic expansion into new markets.
- Strategic acquisitions or partnerships to enhance its pipeline or market reach.
- Leveraging advancements in AI and data analytics for improved diagnostics and treatment planning.
- Increasing demand for precision medicine and targeted therapies.
Threats
- Regulatory hurdles and lengthy approval processes for new products.
- Technological advancements by competitors leading to obsolescence of existing products.
- Changes in healthcare policy and reimbursement rates.
- Supply chain disruptions for critical raw materials.
- Patent expirations and generic competition.
Competitors and Market Share
Key Competitors
- GE HealthCare Technologies Inc. (GEHC)
- Siemens AG (SIEGY)
- Philips N.V. (PHG)
Competitive Landscape
Lantheus Holdings Inc. competes with larger, diversified healthcare companies that offer a broad range of medical imaging solutions. Its advantage lies in its specialized focus on radiopharmaceuticals and its innovative pipeline. However, it faces challenges from established players with significant market share and R&D budgets.
Major Acquisitions
Progenics Pharmaceuticals, Inc.
- Year: 2019
- Acquisition Price (USD millions): 504
- Strategic Rationale: This acquisition significantly expanded Lantheus's oncology portfolio, particularly with the addition of PSMA-targeting radiopharmaceuticals like PYLARIFYu00ae (then known as 18F-DCFPyL), bolstering its position in prostate cancer diagnostics and therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Lantheus Holdings Inc. has shown a strong historical growth trajectory, fueled by the successful commercialization of its diagnostic imaging agents and the recent launch of its therapeutic radiopharmaceuticals. This growth has been supported by strategic investments in R&D and commercial infrastructure.
Future Projections: Analyst estimates project continued strong revenue growth for Lantheus Holdings Inc. in the coming years, driven by the expansion of its product portfolio, particularly in the oncology space, and increasing market adoption of its innovative therapies. The therapeutic radiopharmaceutical segment is expected to be a key growth driver.
Recent Initiatives: Recent strategic initiatives include the successful launch and market penetration of PYLARIFYu00ae, the ongoing development of its pipeline of therapeutic radiopharmaceuticals, and potential strategic partnerships or acquisitions to further strengthen its market position.
Summary
Lantheus Holdings Inc. is a strong player in the growing medical imaging and radiopharmaceutical market, particularly in oncology diagnostics. Its PYLARIFYu00ae launch has been highly successful, driving significant revenue growth. The company's robust R&D pipeline and strategic focus offer substantial future growth potential. However, it must navigate intense competition and regulatory complexities to maintain its upward trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (e.g., 10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Market Research Reports
- Industry Analyst Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The data presented is based on publicly available information and market research, and may not be exhaustive or perfectly up-to-date. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is an estimation and can vary based on reporting methodology and market definition.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantheus Holdings Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2015-06-25 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 808 | Website https://www.lantheus.com |
Full time employees 808 | Website https://www.lantheus.com | ||
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.